Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept for Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed multiple myeloma~  * Stage II or III disease according to Salmon-Durie staging criteria~* Relapsed or refractory disease~* Progressive disease~* Measurable disease, defined by ≥ 1 of the following criteria:~  * Serum M protein ≥ 1.0 g/dL by serum protein electrophoresis~ * Free light chain measurement \> 200 mg/dL~ * Urinary M protein excretion ≥ 200 mg/24 hours~* Must have received ≥ 2 prior therapies\* for multiple myeloma that meet the following criteria:~  * Antimyeloma therapeutic regimen consisting of ≥ 1 complete course of single-agent or combination-agent therapy, or a planned series of treatments (e.g., 3-4 courses of induction therapy followed by a stem cell harvest procedure followed by conditioning high-dose therapy supported by stem cell transplantation)~ * Antimyeloma regimen is discontinued because of the development of resistant disease or severe therapy-related toxicity~ * Individual antimyeloma regimen will be considered to have been discontinued when all agents of the regimen have been permanently stopped~ * A prior regimen will not be considered to have been discontinued for the modification of drug doses, or if less than all the agents of a combination regimen have been discontinued, or if the regimen has been halted temporarily for the development of a plateau phase of myeloma~ * Maintenance therapy will not be considered an additional regimen~ * If new agents are added to an existing regimen, presumably because of tumor resistance, the old regimen will be considered to have ended and a new regimen to have started~* No evidence of central nervous system (CNS) disease, including primary brain tumor or brain metastasis~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100%~* Life expectancy \> 12 weeks~* White blood cell (WBC) ≥ 3,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN~* Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min~* No albuminuria only~  * Urine protein: creatinine ratio \< 1 OR 24-hour urine protein with an albumin level \< 500 mg~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy~Exclusion criteria:~* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies~* No known history of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in the study~* No serious or nonhealing wound, ulcer, or bone fracture~* No significant traumatic injury within the past 28 days~* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days~* No clinically significant cardiovascular disease~* No prothrombin time (PT) or international normalized ratio (INR) \> 1.5 (unless patient is on full-dose warfarin)~* No evidence of bleeding diathesis or coagulopathy~* No uncontrolled intercurrent illness that would limit compliance with study requirements, including ongoing or active infection~* No psychiatric illness or social situations that would limit study compliance~* No concurrent major surgery~* No concurrent immunosuppressive agents (including steroids)~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (antiangiogenesis therapy) (Type: EXPERIMENTAL): Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).